Zobrazeno 1 - 10
of 456
pro vyhledávání: '"John C. Byrd"'
Autor:
Seema A. Bhat, Adam Kittai, Kyle A. Beckwith, Cecelia R. Miller, Ying Huang, Daniel Goldstein, Jennifer A. Woyach, Kerry A. Rogers, Lynne V. Abruzzo, Amy S. Ruppert, Michael R. Grever, John C. Byrd, David A. Bond, Nyla A. Heerema
Publikováno v:
Blood. 138:2372-2382
Complex karyotype, defined as ≥3 cytogenetic abnormalities, is prognostic of survival in patients treated with ibrutinib or venetoclax in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL). Recent studies re-evaluating this dichotomous var
Autor:
Amy S. Ruppert, Larry Beaver, Bonnie K. Harrington, Janek S. Walker, Brandi R. Walker, Katie Williams, James Cronin, Zachary A. Hing, Alexander Pan, Jordan N. Skinner, Jennifer A. Woyach, Nyla A. Heerema, Steven Sher, Amy Lehman, Charles Thomas Gregory, Vincenzo Coppola, Rosa Lapalombella, Krzysztof Mrózek, Max Yano, Pearlly S. Yan, Hatice Gulcin Ozer, James S. Blachly, Jadwiga Labanowska, John C. Byrd, Casey Cempre
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Nature Communications
Nature Communications
Rare, recurrent balanced translocations occur in a variety of cancers but are often not functionally interrogated. Balanced translocations with the immunoglobulin heavy chain locus (IGH; 14q32) in chronic lymphocytic leukemia (CLL) are infrequent but
Autor:
John C. Byrd, Deborah M. Stephens
Publikováno v:
Blood
Bruton tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape for patients with B-cell malignancies, including chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma
Autor:
Charles S. Kuzma, Harry P. Erba, Mark R. Litzow, Steven Coutre, Scott E. Smith, Richard Stone, Amy S. Ruppert, Allison M Booth, Nancy L. Bartlett, Jeremy S. Abramson, John C. Byrd, Jennifer A. Woyach, Jennifer R. Brown, Richard F. Little, Richard A. Larson, Sumithra J. Mandrekar, Wei Ding, Sreenivasa Nattam, Carolyn Owen, Danielle M. Brander
Publikováno v:
Leukemia
Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) compar
Autor:
Kerry A. Rogers, David M. Weiss, Ying Huang, Jennifer A. Woyach, Lynne V. Abruzzo, Nyla A. Heerema, Christin Banks, Allison Dean, Cara Grantier, Barbara L. Andersen, Margaret S. Lucas, Jeffrey A. Jones, Gerard Lozanski, Seema A. Bhat, John C. Byrd, Farrukh T. Awan, Kami J. Maddocks, Amy S. Ruppert, Thomas R. Valentine
Publikováno v:
J Clin Oncol
PURPOSE The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS This phase II study te
Autor:
Richard R. Furman, Lin Tao, Nataliya Kuptsova-Clarkson, Jennifer R. Brown, Wojciech Jurczak, Peter Hillmen, Javid Moslehi, Clare Sun, Paolo Ghia, John M. Pagel, John C. Byrd, Jeff P. Sharman, Priti Patel, Deborah M. Stephens, Alessandra Ferrajoli
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation BTK inhibitor with greater BTK se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0675404d31efe952898ebb286a11f787
https://ruj.uj.edu.pl/xmlui/handle/item/290099
https://ruj.uj.edu.pl/xmlui/handle/item/290099
Autor:
Ian W. Flinn, Emily Liu, William G. Wierda, Richard R. Furman, Jan A. Burger, Susan O'Brien, James P. Dean, John C. Byrd, Ying Luan, Jeff P. Sharman, Steven Coutre, Weiqiang Zhao, Nyla A. Heerema, Kristie A. Blum
Publikováno v:
Clin Cancer Res
Purpose: The safety and efficacy of ibrutinib, a once-daily Bruton's tyrosine kinase (BTK) inhibitor, in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was demonstrated in this phase Ib/II study. Extended follow-up up to 8 years is
Autor:
Ying Huang, James L. Fisher, Erin M. Bertino, Samantha Jaglowski, Kami J. Maddocks, Seema A. Bhat, John C. Byrd, Amy S. Ruppert, David A. Bond, Michael R. Grever, Dwight H. Owen, Jennifer A. Woyach, Kerry A. Rogers
Publikováno v:
Leukemia
7511 Background: Patients (pts) with chronic lymphocytic leukemia (CLL) suffer morbidity and mortality from CLL and increased risk for second primary neoplasia (SPN). BTK inhibitors (BTKi) are highly effective for the treatment (tx) of CLL and are as
Autor:
Anasuya Sarkar, Rakesh A Murugesan, Giovanna Merchand-Reyes, John C. Byrd, Sumithira Vasu, Jonathan P. Butchar, Susheela Tridandapani, Gino M Dettorre, Bethany L. Mundy-Bosse, Nathaniel J Buteyn, Ramasamy Santhanam
Publikováno v:
J Immunol
TLRs, a family of membrane-bound pattern recognition receptors found on innate immune cells, have been well studied in the context of cancer therapy. Activation of these receptors has been shown to induce inflammatory anticancer events, including dif
Autor:
Kyle Porter, Tyler Dickerson, Jennifer Philippon, Kerry A. Rogers, Jennifer A. Woyach, Seema A. Bhat, Daniel Addison, Tracy Wiczer, Avirup Guha, Allyson Waller, Devin Haddad, John C. Byrd, Farrukh T. Awan
Publikováno v:
Blood. 134:1919-1928
Ibrutinib is associated with dramatic efficacy against B-cell malignancies. Yet, ibrutinib is linked with potentially-limiting cardiotoxicity, including emerging reports of profound hypertension. However, the long-term incidence, severity, and impact